Sun, most of Johns Hopkins. On the internet: Song lab, and php.. Baxter commences anti-MIF antibody Stage I actually trial in malignant sound tumors Baxter International Inc. today announced that the business has begun dosing sufferers with malignant solid tumors in a Stage I medical trial of a monoclonal antibody, representing the ongoing company efforts to increase its oncology portfolio with advanced biological research and development. The applicant is a fully-human being, recombinant anti-MIF monoclonal antibody with potential to become a brand-new therapeutic agent in treatment of tumor.The acquisition is at the mercy of customary closing conditions, including the termination or expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Action of 1976. Under the agreement terms, Celgene will acquire Quanticel for an upfront payment of $100 million in cash. Up to an additional $385 million in contingent payments may be achieved upon analysis, development, and regulatory advancements linked to Quanticel's study and development system.

Other entries from category "health news":

Random entries